Abstract:Background Adeno-associated virus-2 (AAV-2)-mediated gene therapy is quite suitable for local or regional application in head and neck cancer squamous cell carcinoma (HNSCC). However, its low transduction efficiency has limited its further development as a therapeutic agent. DNA damaging agents have been shown to enhance AAV-mediated transgene expression. Cisplatin, one of the most effective chemotherapeutic agents, has been recognized to cause cancer cell death by apoptosis with a severe toxicity. This study aims to evaluate the role of cisplatin in AAV-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and the effect on HNSCC both in vitro and in vivo. Methods Five human HNSCC cell lines were treated with recombinant soluble TRAIL (rsTRAIL) and infected with AAV/TRAIL to estimate the sensitivity of the cancer cells to TRAIL-induced cytotoxicity. KB cells were infected with AAV/EGFP with or without cisplatin pretreatment to evaluate the effect of cisplatin on AAV-mediated gene expression. TRAIL expression was detected by ELISA and Western blot. Cytotoxicity was measured by MTT assay and Western blot analysis for caspase-3 and -8 activations. Following the in vitro experiments, TRAIL expression and its tumoricidal activity were analyzed in nude mice with subcutaneous xenografts of HNSCC. Results HNSCC cell lines showed different sensitivities to rsTRAIL, and KB cells possessed both highest transduction efficacy of AAV and sensitivity to TRAIL among five cell lines. Preincubation of KB cells with subtherapeutic dosage of cisplatin significantly augmented AAV-mediated transgene expression in a heparin sulfate proteoglycan (HSPG)-dependent manner. Furthermore, cisplatin enhanced the killing efficacy of AAV/TRAIL by 3-fold on KB cell line. The AAV mediated TRAIL expression was observed in the xenografted tumors and significantly enhanced by cisplatin. AAV/TRAIL suppressed the tumors growth and cisplatin augmented the tumoricidal activity by two-fold. Furthermore, Combination treatment reduced cisplatin-caused body weight loss in nude mice. Conclusion The combination of AAV-mediated TRAIL gene expression and cisplatin had synergistic therapeutic effects on head and neck cancers and reduced the potential toxicity of cisplatin. These findings suggest that the combination of AAV/TRAIL and cisplatin may be a promising strategy for HNSCC therapy.

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma

Effects of TRAIL combined with cisplatin on Hep-2 laryngeal squamous carcinoma in vitro

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Oncolytic Adenovirus Zd55-Trail As A Therapy Against Cervical Cancer

The Apoptotic Pathway of Laryngeal Squamous Carcinoma Cell Line Induced by Combined TRAIL with Chemotherapeutic Drugs or Radiotherapy

VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma.

Oral Adeno-Associated Virus-Strail Gene Therapy Suppresses Human Hepatocellular Carcinoma Growth in Mice

[Basic Research of the Adenovirus-mediated hCTR1 Transfection on the Treatment of Cisplatin Resistant Cervical Cancer]

Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer

Combination of Adenovirus-Mediated TRAIL Gene Therapy and EGFR Target Therapy in NSCLC Cell

Combination of Novel DR5 Targeting Agonistic Scfv Antibody TR2-3 with Cisplatin Shows Enhanced Synergistic Antitumor Activity in Vitro and in Vivo

Combination Nonviral Murine Interleukin 2 And Interleukin 12 Gene Therapy And Radiotherapy For Head And Neck Squamous Cell Carcinoma

Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle–mediated gene expression

Enhanced Antitumor Effect of Combining Interferon Beta with TRAIL Mediated by Tumor-Targeting Adeno-Associated Virus Vector on A549 Lung Cancer Xenograft.

Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.

Synergy of Dendritic Cell Vaccines and Avasimibe in Treatment of Head and Neck Cancer in Mice